ABSTRACT
Introducción: El cuestionario de la enfermedad respiratoria crónica con entrevistador (CRQ-IA) ha demostradoexcelentes propiedades de medida de la calidad de vida relacionada con la salud (CVRS) en pacientescon enfermedad pulmonar obstructiva crónica (EPOC). La validación en español de la versión estandarizadaautoadministrada (CRQ-SAS) no se ha realizado. El objetivo de este estudio fue evaluar la validez yla sensibilidad a los cambios, de la versión española del CRQ-SAS en pacientes con EPOC.Pacientes y métodos: Aleatorizamos a 40 pacientes con EPOC (33 en tratamiento con rehabilitación respiratoriay 7 con oxígeno líquido) a uno de los dos métodos de administración del CRQ (SAS vs. IA) antesy 8 semanas después de la intervención. Los pacientes completaban el cuestionario SF-36, pruebas defunción pulmonar y prueba de los 6 min de marcha.Resultados: El CRQ-SAS ha demostrado una buena validez de constructo longitudinal en todas las áreascon un rango de correlaciones, para las puntuaciones del cambio, entre 0,46 (p = 0,05) y 0,71 (p = 0,01).En cuanto a la sensibilidad a los cambios, se observa un cambio mínimo clínicamente significativo en lamayoría de áreas (fatiga 0,71 [p = 0,02], factor emocional 0,62 [p = 0,04], control de la enfermedad 0,83[p = 0,06]).Conclusiones: La versión española del CRQ-SAS resulta ser válida para evaluar la CVRS de los pacientescon EPOC. Las correlaciones con otros instrumentos aportan validez de constructo y se demuestra unabuena sensibilidad a los cambios(AU)
Introduction: The interviewer-administered chronic respiratory questionnaire (CRQ-IA) is widely usedand has demonstrated excellent properties for measuring health-related quality of life (HRQL) in patientswith chronic obstructive pulmonary disease (COPD). However, the self-administered version (CRQ-SAS)in Spanish has not been validated.The aim of this trial was to evaluate the validity and the sensitivity of the Spanish version of the CRQ-SASin patients with COPD.Material and methods: We randomized 40 patients with COPD (33 treated with pulmonary rehabilitation and 7 with liquid oxygen therapy) to one of the two methods of administration of CRQ (SAS vs. IA) both before and 8 weeks after the treatment. In addition, patients completed the SF-36 questionnaire, pulmonary function tests, and six-minute walk test. Results: The CRQ-SAS demonstrated good longitudinal construct validity on all domains with a rangeof correlations, for the change scores, between 0.46 (P=.05) and 0.71 (P=.01). Regarding sensitivityto change, we observed a minimal clinically significant change in most domains (fatigue 0.71 [P = .02],emotional factor 0.62 [P=.04], control of the disease 0.83 [P=.06]).Conclusions: The Spanish version of CRQ-SAS is valid for evaluating HRQL in COPD patients. Thecorrelations of the CRQ-SAS with other tools provide construct validity and show good sensitivity tochange(AU)
Subject(s)
Humans , Male , Female , Middle Aged , Aged , Quality of Life , Surveys and Questionnaires/standards , Surveys and Questionnaires , Reproducibility of Results/instrumentation , Reproducibility of Results/methods , Reproducibility of Results/standards , Pulmonary Disease, Chronic Obstructive , Dyspnea , Fatigue , Pulmonary Disease, Chronic Obstructive/psychology , Pulmonary Disease, Chronic Obstructive/rehabilitation , Pulmonary Disease, Chronic Obstructive/prevention & controlABSTRACT
INTRODUCTION: The interviewer-administered chronic respiratory questionnaire (CRQ-IA) is widely used and has demonstrated excellent properties for measuring health-related quality of life (HRQL) in patients with chronic obstructive pulmonary disease (COPD). However, the self-administered version (CRQ-SAS) in Spanish has not been validated. The aim of this trial was to evaluate the validity and the sensitivity of the Spanish version of the CRQ-SAS in patients with COPD. MATERIAL AND METHODS: We randomized 40 patients with COPD (33 treated with pulmonary rehabilitation and 7 with liquid oxygen therapy) to one of the two methods of administration of CRQ (SAS vs. IA) both before and 8 weeks after the treatment. In addition, patients completed the SF-36 questionnaire, pulmonary function tests, and six-minute walk test. RESULTS: The CRQ-SAS demonstrated good longitudinal construct validity on all domains with a range of correlations, for the change scores, between 0.46 (P=.05) and 0.71 (P=.01). Regarding sensitivity to change, we observed a minimal clinically significant change in most domains (fatigue 0.71 [P=.02], emotional factor 0.62 [P=.04], control of the disease 0.83 [P=.06]). CONCLUSIONS: The Spanish version of CRQ-SAS is valid for evaluating HRQL in COPD patients. The correlations of the CRQ-SAS with other tools provide construct validity and show good sensitivity to change.
